Creighton Model FertilityCare System

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Creighton Model / FertilityCare
Background
Birth control type Behavioral
First use 1980
Failure rates (first year)
Perfect use 0.5%
Typical use 3.2 (Disputed)%
Usage
Reversibility Immediate
User reminders Accurate instruction & daily charting are key.
Clinic review None
Advantages and disadvantages
STD protection No
Period advantages Prediction
Weight gain No
Benefits Low direct cost;
no side effects;
in accord with Catholic teachings;
may be used to aid pregnancy achievement

The Creighton Model FertilityCare System (Creighton Model, FertilityCare, CrMS) is a form of natural family planning which involves identifying the fertile period during a woman's menstrual cycle. The Creighton Model was developed by Dr Thomas Hilgers, the founder and director of the Pope Paul VI Institute. This model, like the Billings ovulation method, is based on observations of cervical mucus to track fertility.

History[edit]

Dr Thomas Hilgers began research in 1976 which led to the development of the Creighton Model FertilityCare System, which was first fully described (as the Creighton Model) in 1980.[1] In 1981, the American Academy of Natural Family Planning was founded to promote use of the Creighton Model as a form of natural family planning (the term for methods of family planning approved by the Roman Catholic church).[2] In 1985, Hilgers created the Pope Paul VI Institute to medically support the directives given by Pope Paul VI in Humanae Vitae: On the Regulation of Birth.

In 1991, Hilgers self-published a manual titled The Medical Applications Of Natural Family Planning: A Physician’s Guide to NaProTECHNOLOGY through his Pope Paul VI Institute Press. NaProTechnology is described as Natural Procreative Technology. In 2001, the AANFP was renamed the American Academy of FertilityCare Professionals, to reflect the relabeling of the Creighton Model as FertilityCare. In 2004, Hilgers self-published a reference manual titled The Medical and Surgical Practice of NaProTECHNOLOGY. Hilgers refers to the Creighton Model FertilityCare System as "the foundational family planning system to NaProTechnology".

Hilgers describes the Creighton Model as being based on "a standardized modification of the Billings ovulation method", which was developed by John and Evelyn Billings in the 1960s.[1] The Billingses issued a paper refuting the claim that the CrMS represents a standardization of the BOM.[3] They are two different methods and should not be seen as interchangeable.

Overview[edit]

The CrMS teaches women to observe certain biological signs to monitor their own gynaecological health, and to identify times of fertility and infertility. These biological signs include cervical mucus and bleeding patterns, and can be observed and analysed in all types of menstrual cycles. These signs are charted daily to give a picture of the woman's individual cycle.

Doctors can use the fertility charts which couples are taught to keep as the basis for further investigations if needed.

Blood tests for estrogen levels prior to ovulation and for both Progesterone and estrogen levels after ovulation, ultrasound follicular tracking, and other diagnostic procedures, can be accurately timed according to the woman's cycle, using the data recorded on a couple's fertility chart. This allows doctors to make a more precise diagnosis of abnormalities, e.g. subtle hormonal deficiencies, various ovulation defects etc.


Uses[edit]

As a form of fertility awareness or natural family planning, the CrMS may be used to avoid pregnancy, or to increase chances of conception depending on the couple's intentions. The CrMS is used in conjunction with NaProTechnology (Natural Procreative Technology) to treat infertility. It is also used to treat other problems besides infertility such as:


Effectiveness in avoiding pregnancy[edit]

The effectiveness of the CrMS can be assessed two ways. Perfect use or method effectiveness rates only include people who follow all observational rules, correctly identify the fertile phase, and refrain from intercourse on days identified as fertile. Actual use, or typical use effectiveness rates are of all women intending to avoid pregnancy by using CrMS, including those who fail to meet the "perfect use" criteria.[7]

The Pope Paul VI Institute reports a perfect-use effectiveness rate of 99.5% in the first year.[8] In clinical studies of the CrMS conducted at the Pope Paul VI Institute, researchers excluded most pregnancies from the typical-use rate calculation, on the grounds that they believed the affected couples had used the method to deliberately attempt pregnancy.[9] The Institute reports a typical-use effectiveness of 96.8% in the first year.[8] Most studies of similar systems do not exclude such pregnancies from the typical-use failure rate.[10][11] NaproTechnology is more than twice a successful as IVF. Also, lower risk of multiples have been seen in comparison to ART and there has been no observed risk of OHSS.[citation needed] It also costs less than IVF (Hilger, 2006).

Treatment[edit]

  • Use of natural hormones and other medications to correct any hormonal disturbances or ovulation abnormality.
  • Use of medications if necessary to correct any other abnormalities e.g. cervical mucus deficiency, biochemical or haematological deficiencies, endocrine (glandular) deficiencies etc. to restore normal physiologic function, and thereby enhance fertility.
  • Referral to a gynaecologist if there are physical abnormailities needing surgery, for example

References[edit]

  1. ^ a b Creighton Model
  2. ^ American Academy of FertilityCare Professionals
  3. ^ Some Clarifications Concerning NaProTECHNOLOGY and the Billings Ovulation Method
  4. ^ "Premenstrual Syndrome". November 2012. 
  5. ^ "Surgical NaProTECHNOLOGY". November 2012. 
  6. ^ "Postpartum Depression". November 2012. 
  7. ^ Hatcher, RA; Trussel J, Stewart F, et al. (2000). Contraceptive Technology (18th Edition ed.). New York: Ardent Media. ISBN 0-9664902-6-6. 
  8. ^ a b "CREIGHTON MODEL FertilityCare System: Effectiveness of the System". creightonmodel.com. Retrieved 2008-07-16. 
  9. ^ Use effectiveness of the Creighton model ovulation...[J Obstet Gynecol Neonatal Nurs. 1994] - PubMed Result
  10. ^ Weschler, Toni (2002). Taking Charge of Your Fertility (Revised Edition ed.). New York: HarperCollins. pp. 349–350. ISBN 0-06-093764-5. 
  11. ^ Kippley, John; Sheila Kippley (1996). The Art of Natural Family Planning (4th addition ed.). Cincinnati, OH: The Couple to Couple League. pp. 141–142. ISBN 0-926412-13-2. 

Hilgers, Thomas W.,M.D., The NaPro Technology Revolution: unleashing the Power in a Woman's Cycle. New York: Beaufort Books, 2010. Print.

Hilgers, Thomas W. The Medical & Surgical Practice of NaProTECHNOLOGY. Omaha: Pope Paul VI Institute, 2004. N. pag. Print.

Moore, Keith L., T,V.N Persaud, and Mark G. Torchia. Before we are Born Essentials of Embryology and Birth Defects. 8th ed. Philadelphia: Elsevier Inc., 2013. Print.

Unleashing the Power of a Woman's Cycle. Pope Paul VI Institute, 2006. Web. 14 Nov. 2012. <http://www.naprotechnology.com/index.html>.

External links[edit]